Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) - Total Liabilities
Based on the latest financial reports, Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) has total liabilities worth CN¥877.24 Million CNY (≈ $128.37 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 688117 cash generation efficiency to assess how effectively this company generates cash.
Cheng Du Sheng Nuo Biotec Co. Ltd. A - Total Liabilities Trend (2017–2024)
This chart illustrates how Cheng Du Sheng Nuo Biotec Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Cheng Du Sheng Nuo Biotec Co. Ltd. A to evaluate the company's liquid asset resilience ratio.
Cheng Du Sheng Nuo Biotec Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Cheng Du Sheng Nuo Biotec Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sitronix Technology Corp
TW:8016
|
Taiwan | NT$5.49 Billion |
|
Navigator Global Investments Ltd
AU:NGI
|
Australia | AU$164.23 Million |
|
Rezolve AI Limited Ordinary Shares
NASDAQ:RZLV
|
USA | $94.39 Million |
|
Shenzhen Strongteam Decoration Engineering Co Ltd
SHE:002989
|
China | CN¥786.37 Million |
|
Shandong Longhua New Material Co. Ltd.
SHE:301149
|
China | CN¥1.22 Billion |
|
Shenyu Communication Technology Inc
SHE:300563
|
China | CN¥355.83 Million |
|
Imperial Metals Corporation
TO:III
|
Canada | CA$766.00 Million |
|
Gryphon Capital Income Trust
AU:GCI
|
Australia | AU$7.51 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Cheng Du Sheng Nuo Biotec Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cheng Du Sheng Nuo Biotec Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cheng Du Sheng Nuo Biotec Co. Ltd. A (2017–2024)
The table below shows the annual total liabilities of Cheng Du Sheng Nuo Biotec Co. Ltd. A from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥729.58 Million ≈ $106.76 Million |
+67.48% |
| 2023-12-31 | CN¥435.63 Million ≈ $63.75 Million |
+54.88% |
| 2022-12-31 | CN¥281.27 Million ≈ $41.16 Million |
+64.03% |
| 2021-12-31 | CN¥171.48 Million ≈ $25.09 Million |
+10.34% |
| 2020-12-31 | CN¥155.41 Million ≈ $22.74 Million |
+9.09% |
| 2019-12-31 | CN¥142.46 Million ≈ $20.85 Million |
-5.59% |
| 2018-12-31 | CN¥150.90 Million ≈ $22.08 Million |
+41.74% |
| 2017-12-31 | CN¥106.46 Million ≈ $15.58 Million |
-- |
About Cheng Du Sheng Nuo Biotec Co. Ltd. A
ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide,… Read more